Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T18876
(Former ID: TTDC00151)
|
|||||
| Target Name |
Prostaglandin E2 receptor EP4 (PTGER4)
|
|||||
| Synonyms |
Prostanoid EP4 receptor; Prostaglandin E2 receptor EP4 subtype; PTGER2; PGE2 receptor EP4 subtype; PGE receptor EP4 subtype
Click to Show/Hide
|
|||||
| Gene Name |
PTGER4
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 8 Target-related Diseases | + | ||||
| 1 | Asthma [ICD-11: CA23] | |||||
| 2 | Migraine [ICD-11: 8A80] | |||||
| 3 | Pain [ICD-11: MG30-MG3Z] | |||||
| 4 | Transplanted organ/tissue [ICD-11: QB63] | |||||
| 5 | Non-small-cell lung cancer [ICD-11: 2C25] | |||||
| 6 | Heart failure [ICD-11: BD10-BD1Z] | |||||
| 7 | Rectum cancer [ICD-11: 2B92] | |||||
| 8 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
| Function |
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. Has a relaxing effect on smooth muscle. May play an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.
Click to Show/Hide
|
|||||
| BioChemical Class |
GPCR rhodopsin
|
|||||
| UniProt ID | ||||||
| Sequence |
MSTPGVNSSASLSPDRLNSPVTIPAVMFIFGVVGNLVAIVVLCKSRKEQKETTFYTLVCG
LAVTDLLGTLLVSPVTIATYMKGQWPGGQPLCEYSTFILLFFSLSGLSIICAMSVERYLA INHAYFYSHYVDKRLAGLTLFAVYASNVLFCALPNMGLGSSRLQYPDTWCFIDWTTNVTA HAAYSYMYAGFSSFLILATVLCNVLVCGALLRMHRQFMRRTSLGTEQHHAAAAASVASRG HPAASPALPRLSDFRRRRSFRRIAGAEIQMVILLIATSLVVLICSIPLVVRVFVNQLYQP SLEREVSKNPDLQAIRIASVNPILDPWIYILLRKTVLSKAIEKIKCLFCRIGGSRRERSG QHCSDSQRTSSAMSGHSRSFISRELKEISSTSQTLLPDLSLPDLSENGLGGRNLLPGVPG MGLAQEDTTSLRTLRISETSDSSQGQDSESVLLVDEAGGSGRAGPAPKGSSLQVTFPSET LNLSEKCI Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
| HIT2.0 ID | T68O49 | |||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 11 Clinical Trial Drugs | + | ||||
| 1 | 16,16-dimethyl-PGE2 | Drug Info | Phase 2 | Stem cell engraftment | [2] | |
| 2 | BGC-20-1531 | Drug Info | Phase 2 | Migraine | [3], [4] | |
| 3 | ONO-AE1-437 | Drug Info | Phase 2 | Asthma | [5] | |
| 4 | RQ-00000007 (oral) | Drug Info | Phase 2 | Pain | [6], [7] | |
| 5 | IK-007 | Drug Info | Phase 1/2 | Non-small-cell lung cancer | [8] | |
| 6 | AN0025 | Drug Info | Phase 1 | Aggressive cancer | [9] | |
| 7 | E7046 | Drug Info | Phase 1 | Rectal adenocarcinoma | [10] | |
| 8 | ONO-4232 | Drug Info | Phase 1 | Acute heart failure | [11] | |
| 9 | ONO-4578 | Drug Info | Phase 1 | Solid tumour/cancer | [10] | |
| 10 | TPST-1495 | Drug Info | Phase 1 | Solid tumour/cancer | [12] | |
| 11 | PGF2alpha | Drug Info | Clinical trial | Solid tumour/cancer | [13] | |
| Discontinued Drug(s) | [+] 1 Discontinued Drugs | + | ||||
| 1 | ONO-4819 | Drug Info | Discontinued in Phase 2 | Fracture | [14], [15] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Agonist | [+] 22 Agonist drugs | + | ||||
| 1 | 16,16-dimethyl-PGE2 | Drug Info | [16] | |||
| 2 | ONO-AE1-437 | Drug Info | [18] | |||
| 3 | ONO-4232 | Drug Info | [22] | |||
| 4 | PGF2alpha | Drug Info | [24] | |||
| 5 | ONO-4819 | Drug Info | [25], [26], [27] | |||
| 6 | 1-OH-PGE1 | Drug Info | [16] | |||
| 7 | 11-deoxy-PGE1 | Drug Info | [28] | |||
| 8 | 11-deoxy-PGE2 | Drug Info | [24] | |||
| 9 | 13,14-dihydro-PGE1 | Drug Info | [28] | |||
| 10 | 19(R)-OH-PGE2 | Drug Info | [24] | |||
| 11 | butaprost (free acid form) | Drug Info | [24] | |||
| 12 | carbacyclin | Drug Info | [16] | |||
| 13 | cicaprost | Drug Info | [31] | |||
| 14 | CP734432 | Drug Info | [32] | |||
| 15 | KAG-308 | Drug Info | [33] | |||
| 16 | L902688 | Drug Info | [33] | |||
| 17 | M&B 28767 | Drug Info | [16] | |||
| 18 | ONO-AE1-329 | Drug Info | [37] | |||
| 19 | PF-04475270 | Drug Info | [33] | |||
| 20 | PGD2 | Drug Info | [24] | |||
| 21 | TCS 2510 | Drug Info | [33] | |||
| 22 | U46619 | Drug Info | [24] | |||
| Antagonist | [+] 17 Antagonist drugs | + | ||||
| 1 | BGC-20-1531 | Drug Info | [17] | |||
| 2 | RQ-00000007 (oral) | Drug Info | [19] | |||
| 3 | IK-007 | Drug Info | [20] | |||
| 4 | AN0025 | Drug Info | [21] | |||
| 5 | E7046 | Drug Info | [10] | |||
| 6 | ONO-4578 | Drug Info | [10] | |||
| 7 | TPST-1495 | Drug Info | [23] | |||
| 8 | BUTAPROST | Drug Info | [1] | |||
| 9 | AH23848 | Drug Info | [24] | |||
| 10 | CR-5790 | Drug Info | [33] | |||
| 11 | ER819762 | Drug Info | [34] | |||
| 12 | GW 627368 | Drug Info | [36] | |||
| 13 | MK-2894 | Drug Info | [33] | |||
| 14 | ONO-AE2-227 | Drug Info | [38] | |||
| 15 | ONO-AE3-208 | Drug Info | [39] | |||
| 16 | ONO-AE3-240 | Drug Info | [40] | |||
| 17 | RQ-00000008 | Drug Info | [33] | |||
| Inhibitor | [+] 6 Inhibitor drugs | + | ||||
| 1 | 3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid | Drug Info | [29] | |||
| 2 | 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid | Drug Info | [29] | |||
| 3 | 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid | Drug Info | [29] | |||
| 4 | 3-(2-cinnamylphenyl)acrylic acid | Drug Info | [29] | |||
| 5 | 8-aza-11-deoxyprostaglandin E1 | Drug Info | [30] | |||
| 6 | FR-181157 | Drug Info | [35] | |||
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Dinoprostone | Ligand Info | |||||
| Structure Description | Cryo-EM Structure of the Prostaglandin E Receptor EP4 Coupled to G Protein | PDB:7D7M | ||||
| Method | Electron microscopy | Resolution | 3.30 Å | Mutation | Yes | [41] |
| PDB Sequence |
SPVTIPAVMF
28 IFGVVGNLVA38 IVVLCKSRKE48 QKETTFYTLV58 CGLAVTDLLG68 TLLVSPVTIA 78 TYMKGQWPGG88 QPLCEYSTFI98 LLFFSLSGLS108 IICAMSVERY118 LAINHAYFYS 128 HYVDKRLAGL138 TLFAVYASNV148 LFCALPNMGL158 GSSRLQYPDT168 WCFIDWTTQV 178 TAHAAYSYMY188 AGFSSFLILA198 TVLCNVLVCG208 ALLRMHRQFF260 RRIAGAEIQM 270 VILLIATSLV280 VLICSIPLVV290 RVFVNQLYQP300 SLEREVSKNP310 DLQAIRIASV 320 NPILDPWIYI330 LLRKTVLSKA340 IEKIK
|
|||||
|
|
PRO20
4.906
PRO24
3.447
MET27
3.120
PHE28
4.084
GLY68
3.771
THR69
3.080
VAL72
3.412
SER73
3.294
THR76
3.293
TYR80
3.133
LEU99
3.708
PHE102
4.799
|
|||||
| Ligand Name: 4-[4-cyano-2-[[(2R)-2-(4-fluoranylnaphthalen-1-yl)propanoyl]amino]phenyl]butanoic acid | Ligand Info | |||||
| Structure Description | Crystal structure of the human prostaglandin E receptor EP4 in complex with Fab and ONO-AE3-208 | PDB:5YWY | ||||
| Method | X-ray diffraction | Resolution | 3.20 Å | Mutation | Yes | [42] |
| PDB Sequence |
NSPVTIPAVM
27 FIFGVVGNLV37 AIVVLCKSRK47 EQKETTFYTL57 VCGLLVTDLL67 GTLLVSPVTI 77 ATYMKGQWPG87 GQPLCEYSTF97 ILLFFSLSRL107 SIICAMSVER117 YLAINHAYFY 127 SHYVDKRLAG137 LTLFAVYASN147 VLFCALPNMG157 LGSSRLQYPD167 TWCFIDWTTQ 177 VTAHAAYSYM187 YAGFSSFLIL197 ATVLCNVLVC207 GALLRMHAGA266 EIQMVILLIA 276 TSLVVLICSI286 PLVVRVFVNQ296 LYQPSLEREV306 SKNPDLQAIR316 IASVNPILDP 326 WIYILLRKTV336 LSKAIEKIKC346
|
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Pathway Affiliation
Biological Network Descriptors
|
|
| Protein Name | Pfam ID | Percentage of Identity (%) | E value |
|---|---|---|---|
| Olfactory receptor 1M1 (OR1M1) | 26.050 (31/119) | 1.74E-04 | |
| Olfactory receptor 8A1 (OR8A1) | 22.689 (27/119) | 3.00E-03 |
| KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
|---|---|---|---|
| Neuroactive ligand-receptor interaction | hsa04080 | Affiliated Target |
|
| Class: Environmental Information Processing => Signaling molecules and interaction | Pathway Hierarchy | ||
| Inflammatory mediator regulation of TRP channels | hsa04750 | Affiliated Target |
|
| Class: Organismal Systems => Sensory system | Pathway Hierarchy | ||
| Renin secretion | hsa04924 | Affiliated Target |
|
| Class: Organismal Systems => Endocrine system | Pathway Hierarchy | ||
| Degree | 1 | Degree centrality | 1.07E-04 | Betweenness centrality | 0.00E+00 |
|---|---|---|---|---|---|
| Closeness centrality | 2.01E-01 | Radiality | 1.35E+01 | Clustering coefficient | 0.00E+00 |
| Neighborhood connectivity | 3.10E+01 | Topological coefficient | 1.00E+00 | Eccentricity | 12 |
| Download | Click to Download the Full PPI Network of This Target | ||||
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| KEGG Pathway | [+] 4 KEGG Pathways | + | ||||
| 1 | Neuroactive ligand-receptor interaction | |||||
| 2 | Inflammatory mediator regulation of TRP channels | |||||
| 3 | Renin secretion | |||||
| 4 | Pathways in cancer | |||||
| NetPath Pathway | [+] 4 NetPath Pathways | + | ||||
| 1 | FSH Signaling Pathway | |||||
| 2 | IL2 Signaling Pathway | |||||
| 3 | IL4 Signaling Pathway | |||||
| 4 | TGF_beta_Receptor Signaling Pathway | |||||
| Reactome | [+] 2 Reactome Pathways | + | ||||
| 1 | Prostanoid ligand receptors | |||||
| 2 | G alpha (s) signalling events | |||||
| WikiPathways | [+] 6 WikiPathways | + | ||||
| 1 | Prostaglandin Synthesis and Regulation | |||||
| 2 | GPCRs, Class A Rhodopsin-like | |||||
| 3 | Vitamin D Receptor Pathway | |||||
| 4 | Small Ligand GPCRs | |||||
| 5 | GPCR ligand binding | |||||
| 6 | GPCR downstream signaling | |||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. | |||||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3380). | |||||
| REF 4 | ClinicalTrials.gov (NCT00888680) Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine. U.S. National Institutes of Health. | |||||
| REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8541). | |||||
| REF 6 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5858). | |||||
| REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029996) | |||||
| REF 8 | ClinicalTrials.gov (NCT03696212) Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma. U.S.National Institutes of Health. | |||||
| REF 9 | ClinicalTrials.gov (NCT04975958) An Open-Label, Multicenter, Phase 1a Study of AN2025 and AN0025 in Double Combination With Atezolizumab and in Triple Combination With Atezolizumab in Patients With Advanced Solid Tumors. U.S.National Institutes of Health. | |||||
| REF 10 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 11 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039411) | |||||
| REF 12 | ClinicalTrials.gov (NCT04344795) Phase 1a/1b Study of TPST-1495 in Subjects With Solid Tumors. U.S. National Institutes of Health. | |||||
| REF 13 | Stereocontrolled organocatalytic synthesis of prostaglandin PGF2alpha in seven steps. Nature. 2012 Sep 13;489(7415):278-81. | |||||
| REF 14 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1930). | |||||
| REF 15 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016907) | |||||
| REF 16 | Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. | |||||
| REF 17 | BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327. | |||||
| REF 18 | An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90. | |||||
| REF 19 | Clinical pipeline report, company report or official report of Avarx. | |||||
| REF 20 | Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015 Dec 21;2(1):3-9. | |||||
| REF 21 | AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023 Aug;185:109669. | |||||
| REF 22 | ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345. | |||||
| REF 23 | Clinical pipeline report, company report or official report of Tempest Therapeutics. | |||||
| REF 24 | Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. | |||||
| REF 25 | Effect of a prostaglandin EP4 receptor agonist on early fixation of hydroxyapatite/titanium composite- and titanium-coated rough-surfaced implants ... J Biomed Mater Res A. 2010 Mar 1;92(3):1202-9. | |||||
| REF 26 | Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone. 2007 Oct;41(4):543-8. | |||||
| REF 27 | Effects on improvement of blood flow in the chronically compressed cauda equina: comparison between a selective prostaglandin E receptor (EP4) agonist and a prostaglandin E1 derivate. Spine (Phila Pa1976). 2006 Apr 15;31(8):869-72. | |||||
| REF 28 | Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor. Br J Pharmacol. 2000 Aug;130(8):1919-26. | |||||
| REF 29 | Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. | |||||
| REF 30 | Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents. J Med Chem. 2004 Dec 2;47(25):6124-7. | |||||
| REF 31 | The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. | |||||
| REF 32 | Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models. Exp Eye Res. 2009 Nov;89(5):608-17. | |||||
| REF 33 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343). | |||||
| REF 34 | A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010 May;160(2):292-310. | |||||
| REF 35 | Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. J Med Chem. 2005 May 5;48(9):3103-6. | |||||
| REF 36 | Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes. Br J Pharmacol. 2005 Feb;144(3):405-15. | |||||
| REF 37 | The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9. | |||||
| REF 38 | Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002 Jan 1;62(1):28-32. | |||||
| REF 39 | The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002 Apr;109(7):883-93. | |||||
| REF 40 | Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med. 2003 Jan 20;197(2):221-32. | |||||
| REF 41 | Cryo-EM Structure of the Prostaglandin E Receptor EP4 Coupled to G Protein. Structure. 2021 Mar 4;29(3):252-260.e6. | |||||
| REF 42 | Ligand binding to human prostaglandin E receptor EP(4) at the lipid-bilayer interface. Nat Chem Biol. 2019 Jan;15(1):18-26. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.